Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function

NCT01120314 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01120314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01120314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2010
Completion date
July 31, 2011
Enrollment
48 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment